Welcome to our dedicated page for Cardiac Biotech Solutions news (Ticker: CBSC), a resource for investors and traders seeking the latest updates and insights on Cardiac Biotech Solutions stock.
Cardiac Biotech Solutions, Inc. (CBSC) develops, manufactures, and distributes non-invasive ambulatory cardiac monitoring products for remote electrocardiogram data collection. Company news centers on the MyCardia AT cardiac event monitor, also branded as CardioHolter AT in Canada, and related cloud-based acquisition software and mobile applications for iOS, Android, and WeChat.
Recurring updates include regulatory clearances and market-entry work for cardiac monitoring devices, manufacturing and production arrangements, hospital and distributor deployments, international distribution agreements, device purchase orders, and rental programs that pair monitoring hardware with cloud platform access. News also covers corporate-status and governance items such as the company name change, OTC market status, and executive appointments.
CB Scientific (CBSC) is advancing its strategic goals in the Ambulatory Remote Cardiac Monitoring market since June 2020, despite challenges posed by the COVID-19 pandemic. The company highlights key advancements, including the launch of My-Cardia ECG services in Thailand and acquisition plans for DATRIX LLC. Additionally, my-Cam device registrations in Malaysia and Singapore are set for March and April 2021, respectively. Clinical trials are ongoing with over 250,000 successful transmissions. CBSC aims for substantial growth thanks to market expansions and strategic collaborations.
CB Scientific Inc. (CBSC) has entered a collaborative partnership with Shenzhen Semacare Medical Technology to advance remote cardiac monitoring solutions. This partnership aims to leverage Semacare's MetaCor monitoring device and MetaAI technology, facilitating regulatory approvals for both companies' products in international markets. CBSC will assist Semacare in obtaining CE and FDA approvals while receiving support for its my-Cam device in China. The agreement also explores potential joint product development and future strategic business combinations.
CB Scientific (OTC: CBSC) has entered into an exclusive distribution agreement with Mango Wellness Co., Ltd. and My Cardia Thailand Co., Ltd. to launch its FDA and CE-cleared EKG products in Thailand, effective October 29, 2020.
The partnership aims to deliver advanced cardiac monitoring solutions to over 1,300 hospitals in Thailand, addressing the rising incidence of cardiovascular diseases. This move sets the stage for further expansions into Malaysia and Singapore, enhancing CBSC's footprint in the Asian market.